全國服務咨詢熱線：
18438616290
<b id="grzca"><menuitem id="grzca"></menuitem></b>
18438616290
簡要描述：Nafamostat mesylate 82956-11-4Nafamostat mesilate is a synthetic serine protease inhibitor, used as an anticoagulant during hemodialysis.
產(chǎn)品型號：abs47028024廠商性質(zhì)：生產(chǎn)廠家更新時間：2026-01-13訪 問 量：635產(chǎn)品分類
Product Category相關(guān)文章
Related Articles詳細介紹
| 品牌 | absin | CAS | 82956-11-4 |
|---|---|---|---|
| 分子式 | C19H17N5O2.2CH4O3S | 純度 | 99% |
| 分子量 | 539.58 | 貨號 | abs47028024 |
| 規(guī)格 | 100mg | 供貨周期 | 現(xiàn)貨 |
| 主要用途 | used as an anticoagulant during hemodial | 應用領域 | 化工,生物產(chǎn)業(yè),農(nóng)林牧漁,制藥/生物制藥,綜合 |
Nafamostat mesylate 82956-11-4
| 產(chǎn)品描述 | |
| 描述 | Nafamostat mesilate is a synthetic serine protease inhibitor, used as an anticoagulant during hemodialysis. |
| 純度 | 99% |
| 儲存/保存方法 | Store at -20℃ for one year（Powder）；Store at 2-4℃ for two weeks；Store at -20℃ for six months after dissolution. |
| 基本信息 | |
| 別名 | 甲磺酸萘莫司他；FUT-175 |
| 外觀 | 白色至類白色結(jié)晶性 |
| 可溶性/溶解性 | DMSO : 54 mg/mL (100 mM) water : 54 mg/mL (100 mM)l |
| 生物活性 | |
| 靶點 | serine protease |
| In vitro(體外研究) | Nafamostat mesilate significantly inhibits the release of platelet beta-thromboglobulin (beta TG) at 60 and 120 min. Nafamostat mesilate (NM) prevents any significant release of neutrophil elastase; at 120 min, plasma elastase-alpha 1-antitrypsin complex is 0.16 mg/mL in the NM group and 1.24 mg/mL in the control group. Nafamostat mesilate completely inhibits formation of complexes of C1 inhibitor with kallikrein and FXIIa. Nafamostat mesilate inhibits several proteases which may be importantly involved in the pathophysiology of disseminated intravascular coagulation (DIC).Nafamostat mesilate inhibits extrinsic pathway activity (TF-F.VIIa mediated-F.Xa generation) in a concentration dependent manner with IC50 of 0.1 μM. Nafamostat mesilate produces concentration-dependent inhibition of the initial-phase transient component of biphasic ASIC3 currents with an IC50 value of approximately 2.5 mM. |
| In vivo(體內(nèi)研究) | Nafamostat mesilate (10 mg/kg) inhibits scratching induced by tryptase but not by histamine and serotonin. Nafamostat mesilate (1-10 mg/kg) produces the dose-dependent inhibition of scratching induced by intradermal compound 48/80 (10 mg/site). Nafamostat mesilate (10 mg/kg) suppresses tryptase activity in the mouse skin. Nafamostat mesilate inhibits gemcitabine-induced NF-kappaB activation, enhances apoptosis by gemcitabine and suppresses pancreatic tumor growth. Nafamostat mesilate combined with Gemcitabine improves the body weight loss of mice induced by Gemicitabine. |
| 參考文獻 | |
| 參考文獻 |
|
| 研究領域 | |
| 研究領域 | CancerCancer Metabolism CancerTumor immunology MetabolismTypes of disease Drug DiscoverySmall Molecule DrugLead Compound Discovery |
產(chǎn)品咨詢
地址：上海市浦東新區(qū)新浩路58號申江科創(chuàng)園18棟
郵箱：
傳真：